樂
樂觀
樂觀 · 25%SXTC
$2.24
情境價格
$0.111
+0.079 (+71.08%)收盤時
Loading chart…
- 最高
- 0.123
- 開盤
- 0.063
- 成交量加權均價
- 0.10
- 成交量
- 88.06M
- 市值
- 1.01M
- 最低
- 0.061
- 成交金額
- 8.66M
- 企業價值/稅息折舊攤銷前利潤（TTM）
- 0.00
China SXT Pharmaceuticals Inc is a holding company mainly engaged in the research, development, manufacture, marketing and sales of Chinese traditional medicine products (TCMP). The Company sells different types of TCMP products, including Advanced TCMP and Regular TCMP. Advanced TCMP comprises of Directly-Oral-TCMP and After-Soaking-Oral TCMP. Regular TCMP is mainly for hospitals and drug stores for the treatment of various diseases or serving as dietary supplements. The Company sells its products under the brand Suxuantang.
AI 分析 of China SXT Pharmaceuticals Inc (SXTC)
賣出Given the current price of $0.07 and an RSI of 27.828 indicating oversold conditions, SXTC appears to be a risky investment. The stock has experienced a staggering 100% decline year-to-date, and the recent 1-for-150 reverse stock split has not stabilized the share price, which is currently well below the Nasdaq's minimum bid requirement of $1. The main risk is the company's negative earnings with a P/E ratio of -0.082626, reflecting ongoing financial struggles.
估值指標
China SXT Pharmaceuticals Inc（SXTC）目前預期本益比為 0.00，5 年平均預期本益比為 0.00。
Alphio AI 對 SXTC 的價格情境
情境價格取自當年最後一個月度預測區間。機率為固定的模型權重（25 / 50 / 25），不構成保證。
事件時間軸
資訊
8.510-09NewsfilterChina SXT Pharmaceuticals Closes $12 Million Direct Offering
8.510-08PRnewswireChina SXT Pharmaceuticals Announces Direct Offering of 8 Million Shares
- 8.507-24Newsfilter
China SXT Pharmaceuticals Closes $9 Million Direct Offering
8.507-23seekingalphaChina SXT Pharmaceuticals Secures $9M Direct Offering
9.502-02BenzingaDarkIris Inc Reports 27.3% Revenue Growth, Shares Surge
SXTC 常見問題 —— 由 Alphio AI 解答
China SXT Pharmaceuticals Inc is a holding company mainly engaged in the research, development, manufacture, marketing and sales of Chinese traditional medicine products (TCMP). The Company sells different types of TCMP products, including Advanced TCMP and Regular TCMP. Advanced TCMP comprises of Directly-Oral-TCMP and After-Soaking-Oral TCMP. Regular TCMP is mainly for hospitals and drug stores for the treatment of various diseases or serving as dietary supplements. The Company sells its products under the brand Suxuantang. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
Given the current price of $0.07 and an RSI of 27.828 indicating oversold conditions, SXTC appears to be a risky investment. The stock has experienced a staggering 100% decline year-to-date, and the recent 1-for-150 reverse stock split has not stabilized the share price, which is currently well below the Nasdaq's minimum bid requirement of $1. The main risk is the company's negative earnings with a P/E ratio of -0.082626, reflecting ongoing financial struggles.
社群
更多 ↗
$GNPX October 2024 and October 2025. Two Octobers in a row produced strong rallies, and anyone who has followed GNPX closely would recognize that. In 2024 the month finished up about 522%...... The sample is two years, both moves were tied to a thin float, and the current float is even smaller than it was over the last two years, so it may be worth watching for a trade. For that reason, I mentioned GNPX as a potential $SXTC type mover. Let's see what this month brings.
展開
本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。